



## 5.50.040

---

|                    |                         |                              |                 |
|--------------------|-------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs      | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Gastrointestinal Agents | <b>Original Policy Date:</b> | July 5, 2024    |
| <b>Subject:</b>    | Iqirvo                  | <b>Page:</b>                 | 1 of 5          |

---

**Last Review Date:** December 12, 2025

---

### Iqirvo

#### Description

Iqirvo (elafibranor)

---

#### Background

Iqirvo (elafibranor) and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro. However, the mechanism by which Iqirvo exerts its therapeutic effects in patients with primary biliary cholangitis (PBC) is not well understood. Pharmacological activity that is potentially relevant to therapeutic effects includes inhibition of bile acid synthesis through activation of PPAR-alpha and PPAR-delta. The signaling pathway for PPAR-delta was reported to include Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol (1).

#### Regulatory Status

FDA-approved indication: Iqirvo is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA (1).

**Limitations of Use:** Use of Iqirvo is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy) (1).

Iqirvo has been associated with myalgia, myopathy, and rhabdomyolysis. Patients should be assessed for muscle pain and myopathy prior to Iqirvo initiation. Patients with signs or symptoms of new onset or worsening of muscle pain or myopathy should consider periodic assessment (clinical exam, CPK measurement) (1).

---

|                    |                         |                              |                 |
|--------------------|-------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs      | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Gastrointestinal Agents | <b>Original Policy Date:</b> | July 5, 2024    |
| <b>Subject:</b>    | Iqirvo                  | <b>Page:</b>                 | 2 of 5          |

---

Iqirvo use may result in fractures, drug-induced liver injury, and biliary obstruction. Consider risk of fractures and monitor bone health according to current standards of care. Baseline liver function tests should be obtained at treatment initiation with Iqirvo and monitored thereafter. Treatment should be interrupted if liver tests worsen, or if the patient develops signs and symptoms consistent with clinical hepatitis. Consider discontinuation if liver tests worsen after restarting Iqirvo. Avoid use of Iqirvo in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt Iqirvo and treat as clinically indicated (1).

Iqirvo may cause fetal harm when administered during pregnancy. Advise females of reproductive potential to use effective non-hormonal contraceptives or add a barrier method when using hormonal contraceptives during treatment with Iqirvo and for 3 weeks following the last dose of Iqirvo (1).

The safety and effectiveness of Iqirvo in pediatric patients less than 18 years of age have not been established (1).

---

#### Related policies

##### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Iqirvo may be considered **medically necessary** if the conditions indicated below are met.

Iqirvo may be considered **investigational** for all other indications.

### Prior-Approval Requirements

**Age** 18 years of age or older

#### Diagnosis

Patient must have the following:

1. Primary biliary cholangitis (PBC)

|                    |                         |                              |                 |
|--------------------|-------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs      | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Gastrointestinal Agents | <b>Original Policy Date:</b> | July 5, 2024    |
| <b>Subject:</b>    | Iqirvo                  | <b>Page:</b>                 | 3 of 5          |

---

**AND ONE** of the following:

- a. Inadequate response
  - i. History of a minimum of a 1 year trial of ursodeoxycholic acid (UDCA)
- b. Intolerance
  - i. An intolerance which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g., dose reduction) with a history of a trial of ursodeoxycholic acid (UDCA)

**AND ALL** of the following:

- a. Iqirvo must be used in combination with UDCA in patients who are tolerant or used as monotherapy in patients who are unable to tolerate UDCA
- b. Confirmation of diagnosis with elevated serum alkaline phosphatase level

**AND ONE** of the following tests:

- i. Positive antimitochondrial antibody test
- ii. Liver biopsy
- iii. Ultrasound scan of liver

- c. **NO** decompensated cirrhosis
- d. **NO** preliminary biliary obstruction prior to initiation of therapy and agreement to discontinue therapy if complete biliary obstruction develops
- e. Physician agrees to frequently monitor patient during treatment for elevations in liver biochemical tests, development of liver-related adverse reactions, and for changes in serum lipid levels

---

## Prior – Approval Renewal Requirements

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

1. Primary biliary cholangitis (PBC)

**AND ALL** of the following:

- a. Confirmation of patient improvement with **ALL** of the following:
  - i. Serum alkaline phosphatase (ALP) decrease of at least 15%
  - ii. Total bilirubin level of  $\leq 1.1$  mg/dL for females and  $\leq 1.5$  mg/dL for males

---

|                    |                         |                              |                 |
|--------------------|-------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs      | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Gastrointestinal Agents | <b>Original Policy Date:</b> | July 5, 2024    |
| <b>Subject:</b>    | Iqirvo                  | <b>Page:</b>                 | 4 of 5          |

---

- b. The physician has weighed the potential risks against the benefits of continuing treatment in patients experiencing clinically significant liver-related adverse reactions
- c. **NO** decompensated cirrhosis
- d. **NO** evidence of complete biliary obstruction
- e. Physician agrees to frequently monitor patient during treatment for elevations in liver biochemical tests, development of liver-related adverse reactions, and for changes in serum lipid levels

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Quantity** 90 tablets per 90 days

**Duration** 6 months

---

### Prior – Approval Renewal Limits

**Quantity** 90 tablets per 90 days

**Duration** 12 months

## Rationale

### Summary

Iqirvo (elafibranor) is a PPAR agonist indicated for the treatment of PBC. Iqirvo is not recommended in patients who have or develop decompensated cirrhosis. Iqirvo has been associated with myalgia, myopathy, rhabdomyolysis, fractures, potential risk to a fetus, drug-induced liver injury, and biliary obstruction. The safety and effectiveness of Iqirvo in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Iqirvo while maintaining optimal therapeutic outcomes.

|                    |                         |                              |                 |
|--------------------|-------------------------|------------------------------|-----------------|
| <b>Section:</b>    | Prescription Drugs      | <b>Effective Date:</b>       | January 1, 2026 |
| <b>Subsection:</b> | Gastrointestinal Agents | <b>Original Policy Date:</b> | July 5, 2024    |
| <b>Subject:</b>    | Iqirvo                  | <b>Page:</b>                 | 5 of 5          |

---

## References

1. Iqirvo [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; June 2024.

## Policy History

| Date           | Action   |
|----------------|--|
| July 2024      | Addition to PA   |
| September 2024 | Annual review. Per FEP, added managed PA verbiage to requirements  |
| December 2024  | Annual review. Per SME, updated UCDA t/f requirements and added liver monitoring requirements to match Ocaliva |
| June 2025      | Annual review  |
| December 2025  | Annual review. Removed from managed PA   |

## Keywords

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 12, 2025 and is effective on January 1, 2026.**